Literature DB >> 23685375

What is a health benefit? An evaluation of EFSA opinions on health benefits with reference to probiotics.

K H Binnendijk1, G T Rijkers.   

Abstract

Probiotics are microorganisms that have a beneficial effect on the health of the host. However, before these effects can be referred to as beneficial to human health, such claims need to be evaluated by regulatory institutes such as the European Food Safety Authority (EFSA). The EFSA Panel on Dietetic Products, Nutrition and allergies (NDA) has published their opinions regarding health claims including probiotics, most of which were rejected in the past years. Using the EFSA database, the NDA dossiers published between 2005 and 2013 were analysed to provide an overview on what grounds certain health effects were accepted as beneficial and others not. The NDA Panel distinguishes between claims that are definitely beneficial, possibly beneficial or non-beneficial to human health. Overall, 78% of all analysed health claims are considered by the NDA Panel as (possibly) beneficial to human health, in particular the gut health effects. Since, in many cases, the scientific substantiation of a particular health claim was deemed insufficient, most applications were turned down. For future health claim applications concerning probiotics to be successful, they should include specific statements on what exactly the microorganism affects, and the scientific substantiation of the particular health claim should be based on the targeted (general) population.

Entities:  

Mesh:

Year:  2013        PMID: 23685375     DOI: 10.3920/BM2013.0019

Source DB:  PubMed          Journal:  Benef Microbes        ISSN: 1876-2883            Impact factor:   4.205


  7 in total

Review 1.  Nutraceuticals as modulators of gut microbiota: Role in therapy.

Authors:  Eamonn M M Quigley
Journal:  Br J Pharmacol       Date:  2020-01-03       Impact factor: 8.739

2.  A review of the systematic review process and its applicability for use in evaluating evidence for health claims on probiotic foods in the European Union.

Authors:  Julie Glanville; Sarah King; Francisco Guarner; Colin Hill; Mary Ellen Sanders
Journal:  Nutr J       Date:  2015-02-08       Impact factor: 3.271

Review 3.  Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review.

Authors:  Lynne V McFarland
Journal:  BMJ Open       Date:  2014-08-25       Impact factor: 2.692

4.  Functional Characterization of Novel Faecalibacterium prausnitzii Strains Isolated from Healthy Volunteers: A Step Forward in the Use of F. prausnitzii as a Next-Generation Probiotic.

Authors:  Rebeca Martín; Sylvie Miquel; Leandro Benevides; Chantal Bridonneau; Véronique Robert; Sylvie Hudault; Florian Chain; Olivier Berteau; Vasco Azevedo; Jean M Chatel; Harry Sokol; Luis G Bermúdez-Humarán; Muriel Thomas; Philippe Langella
Journal:  Front Microbiol       Date:  2017-06-30       Impact factor: 5.640

5.  Cost-benefit relation of diet and probiotics in iatrogenic bowel irregularity (IBI).

Authors:  Eric Claassen
Journal:  Front Pharmacol       Date:  2014-02-17       Impact factor: 5.810

Review 6.  Considerations for the design and conduct of human gut microbiota intervention studies relating to foods.

Authors:  J R Swann; M Rajilic-Stojanovic; A Salonen; O Sakwinska; C Gill; A Meynier; P Fança-Berthon; B Schelkle; N Segata; C Shortt; K Tuohy; O Hasselwander
Journal:  Eur J Nutr       Date:  2020-04-03       Impact factor: 5.614

Review 7.  Overview of the Importance of Biotics in Gut Barrier Integrity.

Authors:  Aleksandra Maria Kocot; Elżbieta Jarocka-Cyrta; Natalia Drabińska
Journal:  Int J Mol Sci       Date:  2022-03-07       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.